Barclays maintains Buy rating for
Henry Schein (HSIC). The company executives are seen making various open-market transactions with multiple executives surrendering shares to cover tax withholdings. Henry Schein demonstrates solid growth prospects, attracting analysts to reassess growth and valuation, alongside
Dental Equipment & Technology Stocks’ Q4 Earnings reflection. HSIC also receives praise for its ethical business practices, with Ethisphere naming it one of the
World’s Most Ethical Companies® for the 15th consecutive year. HSIC’s short interest dropped 12.8% in February. With positive reviews on Q4 earnings and revenue, and some executives receiving new stock option and RSU awards. The company even surpasses Q4 Earnings and Revenue estimates and strengthens its position with the unveiling of a new Dallas Discovery Centre.
Piper Sandler expresses bullish sentiment, maintaining the Buy Rating while raising the target price. Keep an eye out for their upcoming March investor talks. Zacks Research shows negative view on Q1 Earnings, and the company's CEO undergoes transition. There also seems to be ongoing insider trading activity along with steady share disposals tied to award vesting.
Henry Schein HSIC News Analytics from Wed, 17 Sep 2025 07:00:00 GMT to Sat, 21 Mar 2026 07:31:56 GMT -
Rating 8
- Innovation -2
- Information 7
- Rumor 2
